Abstract
This multicentre, doubleblind, parallel-group study compared the efficacy, safety and tolerability of oral sumatriptan, given as a new film-coated tablet, with placebo in the acute treatment of migraine. Patients were randomised unequally (1:2) to receive placebo or sumatriptan. Eighty-eight patients received placebo (plus an optional dose 2 h later if the headache persisted plus a further optional dose for recurrence within 24 h) and 162 patients received sumatriptan 100 mg (plus an optional 100 mg dose at 2 h and an optional 100 mg dose within 24 h). Sumatriptan was significantly more effective than placebo at relieving headache (defined as reduction in severity from severe or moderate pain to mild or no pain) at 2 h (51% versus 31%,P = 0.003) and 4 h (71% versus 35%,P < 0.001). Fewer sumatriptan-treated patients required a second dose compared with placebo-treated patients (49% versus 74%,P < 0.001). More sumatriptan-treated patients were completely pain free compared with placebo-treated patients at both 2 h (24% versus 12%) and 4 h (48% versus 18). Patients receiving sumatriptan reported earlier onset of headache relief than patients receiving placebo. Headache relief in sumatriptan-treated patients was similar, irrespective of the type of migraine (with or without aura) or the time of treatment ≤ 4 h or > 4 h after onset of migraine). Sumatriptan was more effective than placebo at relieving nausea, vomiting and photophobia/phonophobia. Few patients were evaluable for treatment of headache recurrence, and statistical analysis was not possible. More sumatriptan-treated patients than placebo-treated patients reported adverse events (29% versus 16%) but the difference was not significant at the 5% level. Most of these events were mild to moderate in severity, of short duration and resolved without treatment. Sumatriptan had no clinically significant effect on blood pressure, heart rate, electrocardiogram or laboratory test results. It is concluded that oral sumatriptan 100 mg, given as a film-coated tablet, provides an effective and well-tolerated acute treatment for migraine.
Similar content being viewed by others
References
Brown EG, Endersby CA, Smith RN, Talbot JCC (1991) The safety and tolerability of sumatriptan: an overview. Eur Neurol 31:339–344
Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Shaggs H (1991) Treatment of acute migraine with subcutaneous sumatriptan. DAMA 265:2831–2835
Connor HE, Feniuk W, Lloyd K, Humphrey PPA (1992) Migraine, serotonin and sumatriptan. Vascular Med Rev 3:95–108
Headache Classification Committee of the International Headache Society (1988) Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8 [Suppl 7]:1–96
The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group (1992) A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol 32:177–184
The Oral Sumatriptan Dose-Defining Study Group (1991) Sumatritpan — an oral dose-defining study. Eur Neurol 31:300–305
The Oral Sumatriptan International Multiple-Dose Study Group (1991) Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 31:306–313
The Subcutaneous Sumatriptan International Study Group (1991) Treatment of migraine attacks with sumatriptan. N Engl J Med 325:316–321
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nappi, G., Sicuteri, F., Byrne, M. et al. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 241, 138–144 (1994). https://doi.org/10.1007/BF00868340
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00868340